Hyperion DeFi (NASDAQ:HYPD) Shares Down 8.5% – Here’s Why

Hyperion DeFi, Inc. (NASDAQ:HYPD)’s share price traded down 8.5% on Tuesday . The stock traded as low as $3.72 and last traded at $3.79. 402,642 shares changed hands during mid-day trading, a decline of 17% from the average session volume of 483,909 shares. The stock had previously closed at $4.14.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HYPD. Cantor Fitzgerald began coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target for the company. Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Thursday, January 22nd. Zacks Research raised Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Finally, Chardan Capital set a $7.75 price objective on shares of Hyperion DeFi and gave the company a “buy” rating in a research report on Wednesday, December 24th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.58.

Hyperion DeFi Price Performance

The stock has a market cap of $30.96 million, a price-to-earnings ratio of -0.94 and a beta of 2.69. The company’s 50-day moving average is $3.58 and its 200-day moving average is $5.89. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11.

Insider Buying and Selling

In other news, Director Michael S. Geltzeiler bought 30,000 shares of the stock in a transaction dated Wednesday, December 17th. The shares were acquired at an average price of $3.01 per share, with a total value of $90,300.00. Following the acquisition, the director owned 88,015 shares in the company, valued at $264,925.15. This trade represents a 51.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Happy David Walters bought 61,930 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were purchased at an average price of $3.02 per share, with a total value of $187,028.60. Following the transaction, the director directly owned 111,930 shares in the company, valued at $338,028.60. This represents a 123.86% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 189,204 shares of company stock worth $611,467 in the last quarter. Corporate insiders own 10.86% of the company’s stock.

Institutional Trading of Hyperion DeFi

Large investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $38,000. Nations Financial Group Inc. IA ADV bought a new position in Hyperion DeFi in the 4th quarter valued at $40,000. Price T Rowe Associates Inc. MD acquired a new position in Hyperion DeFi in the fourth quarter worth $73,000. Formidable Asset Management LLC acquired a new position in Hyperion DeFi in the fourth quarter worth $83,000. Finally, State Street Corp bought a new stake in shares of Hyperion DeFi during the fourth quarter worth $92,000. 25.84% of the stock is owned by institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.